New IFPMA Corporate Brochure - Committed to a Healthier Future
We hope you find this brochure informative to gain better understanding of the contributions of our industry. We are passionate about the role we play in finding effective and sustainable solutions to today’s most pressing health concerns and look forward to continuing the dialogue with our partners
Read More
Pharma by numbers
In a simple click, find out what we bring to your country and to the world! This platform features key data and statistics for global health and pharma contribution at country and global levels.
Read More
IFPMA HEALTH PARTNERSHIPS DIRECTORY
IFPMA hosts the Health Partnerships Directory, a continuously expanding online database that allows users to view, in depth, health partnerships from across the world that involve the research-based biopharmaceutical industry.
Read More
IFPMA Reception during WHA - 23 May 2016
Zika & Ebola: How global health threats prompt innovation
Read More
Our response to Zika outbreak
In early February 2016, WHO had declared Zika virus disease a public health emergency of international concern. Check out here our weapons against Zika.
Read MoreIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Innovative financing into hepatitis B and C prevention and treatment in low and middle income countries
Read More
Innovative financing into hepatitis B and C prevention and treatment in low and middle income countries
Read More
IFPMA 2016 Geneva Pharma Forum on Biotherapeutics - Long version
Watch what healthcare stakeholders and regulatory experts are saying today about the opportunities & challenges facing biotherapeutic medicines. On more details of this event, click here: http://www.ifpma.org/events-2/biotherapeutic-medicines-a-winning-formula-for-patients/
Read More
Innovative sources of financing to help scale up prevention and treatment of viral hepatitis in low and middle-income countries
Breakthroughs in the treatment of hepatitis C pose questions on how to make innovations more available to a large number of patients. A new report looks at possible innovative funding solutions for low and middle-income countries (LMICs) to scale up treatments for viral hepatitis and support health systems to deliver...
Read More
IFPMA 2016 interview series on 'The R&D challenges in tackling Zika virus'
IFPMA 2016 interview series on ‘The R&D challenges in tackling Zika virus’ As part of our latest interview series, we sat down with Dr. Ted Tsai to discuss the current R&D challenges in the fight against Zika virus. Dr. Ted Tsai, a vaccine expert from Takeda, took part in...
Read More
Our take on Zika virus
Our take on Zika virus Geneva, 3 March 2016 − The International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, which includes some of the world’s leading manufacturers of vaccines, confirms that there is currently no approved vaccine or treatment for Zika virus (ZIKV) available. On 1 February 2016, the World...
Read More
Join IFPMA
There are many challenges in improving public health policy for current and future generations. To play an effective role in advancing these policies, the research-based biopharmaceutical industry needs an informed and credible voice in the conversation with the global health community. That voice is IFPMA.
LEARN MOREOur Blog
Eliminating a ‘silent killer’: innovative sources of financing to help meet costs of prevention and treatment of viral hepatitis
Viral hepatitis – a silent, but preventable epidemic Recent breakthroughs in available treatment options and the broader objectives of the health-related Sustainable Development Goals (SGDs) make the WHO target of eliminating viral hepatitis by 2030 feasible. Earlier this week, the WHO issued updated guidelines for the treatment of hepatitis C infection, to “promote the transition to newer, more effective medicines that have the potential to...
Read More
An important milestone in the search for an Ebola vaccine
It seems there is always a new story in the media about an emerging health threat. Right now, understandably, there is significant public concern about the spread of the Zika virus. But just over a year ago, it was the Ebola virus and its devastating impact in West Africa that dominated the headlines. The Ebola epidemic in West Africa may have subsided, but not after...
Read More
Biotherapeutic medicines: a winning formula for patients
Biotherapeutics play an important role in modern medicine and have a profound impact on patients with serious diseases. A biotherapeutic is a medical product manufactured or extracted from biological sources. Composed of larger and more complex molecules than chemically-synthesized medicines, biotherapeutic medicines require sophisticated production and control processes in order to maintain their safety and efficacy over time. In recent years, the expiration of patents...
Read MoreLatest Tweets
